Wednesday, March 29, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Antimicrobial Resistance

Breakthrough Discovery to Help Fight Antibiotic Resistance

by Global Biodefense Staff
June 12, 2013

Gut Viruses: An Artistic RenderingResearchers from the Wyss Institute for Biologically Inspired Engineering at Harvard have found that bacteria in the gut under attack by antibiotics have allies no one had ever anticipated. Gut viruses that usually commandeer the bacteria actually enable them to survive the antibiotic onslaught, most likely by handing them genes that help them withstand the drug.

The gut viruses, called bacteriophage or simply phage, deliver genes that help the bacteria to survive not just the antibiotic they’ve been exposed to, but other types of antibiotics as well. That suggests that phages in the gut may be partly responsible for the emergence of dangerous superbugs that withstand multiple antibiotics, and that drug targeting of phages could offer a potential new path to mitigate development of antibiotic resistance.

“The results mean that the antibiotic-resistance situation is even more troubling than we thought,” said senior author Jim Collins, Ph.D., a pioneer of synthetic biology and Core Faculty member at the Wyss Institute for Biologically Inspired Engineering, who is also the William F. Warren Distinguished Professor at Boston University, where he leads the Center of Synthetic Biology.

Certain bacteria have adapted to antibiotics faster than scientists can generate new drugs to kill them, creating a serious threat to global health. Patients who are hospitalized with serious bacterial infections tend to have longer, more expensive hospital stays, and they are twice as likely to die as those infected with antibiotic-susceptible bacteria, according to the World Health Organization. In addition, because first-line drugs fail more often than before, more expensive therapies must be used, raising health-care costs.

In the past, Collins and other scientists have probed the ways gut bacteria adapt to antibiotics, but they’ve focused on the bacteria themselves. But Collins and Sheetal Modi, Ph.D., the lead author of the study and a postdoctoral fellow in Collins’ laboratory and at the Wyss Institute, knew that phage were also abundant in the gut, and that they were adept at ferrying genes from one bacterium to another.

The researchers wondered whether treating mice with antibiotics led phage in the gut to pick up more drug-resistance genes, and if so, whether that made gut bacteria stronger. 

They gave mice either ciprofloxacin or ampicillin – two commonly prescribed antibiotics. After eight weeks, they found that the phages from antibiotic-treated mice carried significantly higher numbers of bacterial drug-resistance genes than they would have carried by chance. Additionally, phage from ampicillin-treated mice carried more genes that help bacteria fight off ampicillin and related penicillin-like drugs, while phage from ciprofloxacin-treated mice carried more genes that help them fight off ciprofloxacin and related drugs.

“When we treat mice with certain classes of drugs, we see enrichment of resistance genes to those drug classes,” Modi said.

The phage did more than harbor drug-resistance genes. They could also transfer them back to gut bacteria – a necessary step in conferring drug resistance. The researchers demonstrated this by isolating phage from either antibiotic-treated mice or untreated mice, then adding those phage to gut bacteria from untreated mice. Phage from ampicillin-treated mice tripled the amount of ampicillin resistance, while phage from ciprofloxacin-treated mice doubled the amount of ciprofloxacin resistance.

That was bad enough, but the scientists also found signs that the phage could do yet more to foster antibiotic resistance. That’s because gut phage from mice treated with one drug carried high levels of genes that confer resistance to different drugs, which means that the phage could serve as backup when bacteria must find ways to withstand a variety of antibiotics. 

“With antibiotic treatment, the microbiome has a means to protect itself by expanding the antibiotic resistance reservoir, enabling bugs to come back to be potentially stronger and more resistant than before,” Collins said. 

“Antibiotic resistance is as pressing a global health problem as they come, and to fight it, it’s critical to understand it,” said Don Ingber, M.D., Ph.D., Wyss Institute Founding Director. “Jim’s novel findings offer a previously unknown way to approach this problem by targeting the phage that live in our intestine, rather than the pathogens themselves.” 

Source: adapted from Wyess Institute for Biologically Inspired Engineering

IMAGE: Gut Viruses: An Artistic Rendering by Jenn Hinle. Gut viruses called bacteriophage, or phage (red), protect the gut bacteria they infect (blue) from antibiotics by harboring antibiotic-resistance genes. The findings mean that drugs that target phages could offer a potential new path to mitigate antibiotic resistance.

Tags: AntimicrobialsEmerging ThreatsSynthetic Biology

Related Posts

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions
Pathogens

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
The device appears smaller than a playing card, transparent, with visible channels branching off.
Medical Countermeasures

How Organ-on-a-chip Models Could Grease the Drug Development Pipeline

January 10, 2023
New Virus Discovered in Swiss Ticks
Biosurveillance

New Virus Discovered in Swiss Ticks

December 7, 2022
Load More

Latest News

Biodefense Headlines – 26 March 2023

March 26, 2023
Biodefense Headlines – 12 March 2023

Biodefense Headlines – 12 March 2023

March 12, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC